VRX.TO - Valeant Pharmaceuticals International, Inc.

Toronto - Toronto Delayed Price. Currency in CAD
25.86
+0.75 (+2.99%)
As of 10:16AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close25.11
Open25.17
Bid25.86 x 0
Ask25.87 x 0
Day's Range24.58 - 26.13
52 Week Range11.20 - 29.28
Volume2,399,816
Avg. Volume1,977,264
Market Cap8.881B
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Why Sanderson Farms, Valeant Pharmaceuticals International, and Criteo Slumped Today
    Motley Fool18 hours ago

    Why Sanderson Farms, Valeant Pharmaceuticals International, and Criteo Slumped Today

    Find out the latest company that mentioned the NFL's impact on its business.

  • Barrons.com19 hours ago

    Valeant: Down It Goes!

    Everything's been going so well for Valeant Pharmaceuticals International (VRX). See, Valeant has been on quite a run. Since bottoming at $8.51 in April, Valeant's shares have rallied more than 130% as the beleaguered pharmaceutical company sold off assets, and paid down or extended its debt.

  • SmarterAnalyst21 hours ago

    Valeant Pharmaceuticals Intl Inc (VRX) Has A New Bear In Town

    Have Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares just gotten too expensive? Shares are tumbling 10% after a cautious analyst decided it is no longer wise to play it safe, deciding to step away from the sidelines on VRX. The reason? The struggling biotech giant's estimates for the next two years seem too ambitious. Moreover, now after shares have rallied close to 100% from the stock price before the third quarter print, Valeant's valuation simply does not make a "compelling" argument to invest.

  • MarketWatch21 hours ago

    These 4 stocks are powering higher

    News and strong technical momentum are behind these gains.

  • Market Realist22 hours ago

    Valeant Pharmaceuticals’ Siliq Approved for Plaque Psoriasis

    In February 2017, the FDA (Food and Drug Administration) approved Valeant Pharmaceuticals' (VRX) Siliq injection for the treatment of adults with moderate to severe plaque psoriasis.

  • MarketWatchyesterday

    Valeant's stock drops after J.P. Morgan turns bearish

    Shares of Valeant Pharmaceuticals International Inc. dropped 4.3% in premarket trade Thursday, after the drug maker was downgraded at J.P. Morgan, which cited valuation and concerns over patent losses ...

  • Valeant (VRX) Touches 52-Week High: Is the Stock Officially Back?
    Zacks2 days ago

    Valeant (VRX) Touches 52-Week High: Is the Stock Officially Back?

    Shares of Valeant Pharmaceuticals (VRX) surged more than 2% higher on Wednesday morning, touching a new 52-week high in the process. As we approach the New Year, it is time to ask: is Valeant officially back?

  • Barrons.com3 days ago

    This Porridge Is Too Hot: Valeant Bears Abandon the Stock

    Shares of Valeant Pharmaceuticals International (VRX) are higher Tuesday, and have easily outperformed this year, to the point that shorts may be throwing in the towel. Today, Cantor Fitzgerald's Louise Chen and her team write that the company has also seen the largest decrease in short interest in her coverage universe as of the end of November. The move comes as Valeant rose from less than $15 in mid-month to nearly $22 today.

  • Reuters3 days ago

    CANADA STOCKS-TSX advances, lifted by Valeant, financial services

    Canada's main stock index rose on Tuesday, led by gains in drugmaker Valeant Pharmaceuticals and in the financial services sector. * At 10:18AM ET , the Toronto Stock Exchange's S&P/TSX composite index ...

  • Benzinga3 days ago

    PreMarket Prep Trade Of The Day: Valeant Is On Fire

    Every day on PreMarket Prep, hosts Joel Elconin and Dennis Dick highlight over a dozen key morning movers to keep an eye on throughout the day. Below is a trade we thought is particularly hot today. Valeant ...

  • Valeant Climbs to Its Highest Level in More Than a Year
    Bloomberg4 days ago

    Valeant Climbs to Its Highest Level in More Than a Year

    Don’t look now, but Valeant Pharmaceuticals International Inc. is at its highest level in more than a year.

  • Valeant (VRX) in Focus: Stock Moves 11.7% Higher
    Zacks4 days ago

    Valeant (VRX) in Focus: Stock Moves 11.7% Higher

    Valeant Pharmaceuticals International (VRX) was a big mover last session, as the company saw its shares rise nearly 12% on the day.

  • Reuters7 days ago

    Drug industry group sues to stop California drug price law

    The trade group representing U.S. drugmakers on Friday said it has a filed a lawsuit to stop California from implementing a law aimed at reining in prescription drug prices. The Pharmaceutical Research and Manufacturers of America (PhRMA), in a statement, said it filed litigation in the U.S. District Court for the Eastern District of California challenging a state law requiring drug manufacturers to give notice and a justification for price increases of certain drugs. The law, Senate Bill 17, was signed by California Governor Jerry Brown in October and is set to take effect Jan. 1, 2019.

  • Bill Ackman Likely to Face Trial on Allergan Insider-Trading Claims
    Bloomberg7 days ago

    Bill Ackman Likely to Face Trial on Allergan Insider-Trading Claims

    Activist investor Bill Ackman and his estranged former collaborator in a 2014 hostile takeover bid for Botox-maker Allergan Inc. will likely face a jury trial next month over claims they engaged in insider ...

  • What's Behind Valeant Pharmaceuticals Inc.'s 11% Move Higher?
    Motley Fool7 days ago

    What's Behind Valeant Pharmaceuticals Inc.'s 11% Move Higher?

    Carryover news and a broad market rally appear to be fueling Valeant's stock on an event-free day.

  • Benzinga8 days ago

    Vetr Upgrades Valeant After Price Dips

    The Vetr crowd on Thursday upgraded its rating on Valeant Pharmaceuticals International, Inc. (NYSE: VRX ), from 4 stars (Buy), issued two days ago, to 5 stars. Crowd sentiment at the time of the upgrade ...

  • Reuters8 days ago

    CANADA STOCKS-TSX rises with energy stocks, financials

    Canada's main stock index rose on Thursday, boosted by gains for financial and energy stocks and bounceback rises for discount store chain Dollarama Inc , commerce software company Shopify and Valeant ...

  • See what the IHS Markit Score report has to say about Valeant Pharmaceuticals International Inc.
    Markit8 days ago

    See what the IHS Markit Score report has to say about Valeant Pharmaceuticals International Inc.

    Valeant Pharmaceuticals International Inc NYSE:VRX

  • Valeant Catches the Eye of Investors After 97% Plummet
    Bloomberg9 days ago

    Valeant Catches the Eye of Investors After 97% Plummet

    Two years ago, Valeant Pharmaceuticals International Inc. shares plunged off a cliff. Now, some investors are starting to pick them up and dust them off.

  • The Undeniable Reason Behind Valeant Pharmaceuticals Inc.'s 43% Rally in November
    Motley Fool9 days ago

    The Undeniable Reason Behind Valeant Pharmaceuticals Inc.'s 43% Rally in November

    Baby steps have been taken, but there's still a long way for this company to go.

  • How Ackman Hopes to Beat Insider-Trading Lawsuit: QuickTake Q&A
    Bloomberg9 days ago

    How Ackman Hopes to Beat Insider-Trading Lawsuit: QuickTake Q&A

    Billionaire investor Bill Ackman’s audacious partnership with Valeant Pharmaceuticals International Inc. to make a hostile bid for drug company Allergan Inc. in 2014 brought him a windfall of more than ...

  • SmarterAnalyst10 days ago

    Investing Guru Jim Simons Rolls Out the Red Carpet for Valeant Pharmaceuticals, Cuts Opko Health

    Jim Simons, the founder of one of the world's most successful hedge funds, is splashing out on controversial healthcare stock Valeant Pharmaceuticals (NYSE:VRX). However, this fund guru is displaying a more cautious attitude towards Opko Health (NASDAQ:OPK). Will these moves take his $85 billion fund to new heights?

  • Valeant Pharmaceuticals Joins Elite Club Of Stocks With RS Ratings Over 90
    Investor's Business Daily10 days ago

    Valeant Pharmaceuticals Joins Elite Club Of Stocks With RS Ratings Over 90

    Valeant Pharmaceuticals sees its Relative Strength Rating move into the elite 90-plus level.

  • Valeant Returns to Bond Market to Refinance Debt Due in 2020
    Bloomberg11 days ago

    Valeant Returns to Bond Market to Refinance Debt Due in 2020

    Valeant Pharmaceuticals International Inc., returned to the bond market to start refinancing the more than $4 billion of junk debt that the drugmaker has coming due starting in just over two years. Valeant is weighed down by a $27 billion debt load that it accumulated to fund acquisitions. Valeant has cut its debt burden from around $30 billion at the start of the year through these measures.

  • SmarterAnalyst11 days ago

    Is Valeant Cured of Headwinds? Analyst Sheds Light Following Meeting with Management

    Valeant Pharmaceuticals (NYSE:VRX) management boiled down its position to BTIG analyst Tim Chiang, where the discussion gravitated on the standing of the company's three leading segments: Bausch + Lamb/International, Branded Rx, and U.S. Diversified products. The biotech giant is not out of the woods, says Chiang after talking over the company's bigger picture with the VRX team. However, does some growth potential remain for this comeback kid of the Street just yet?